Dottorato in Medicina Molecolare

Bandini S, Macagno M, Hysi A, Lanzardo S, Conti L, Bello A, Riccardo F, Ruiu R, Merighi I F, Forni G, Iezzi M, Quaglino E and Cavallo F, The non inflammatory role of C1q during Her2/neu driven mammary carcinogenesis. OncoImmunology  (accepted for publication)

Conti L, Lanzardo S, Ruiu R, Cadenazzi M, Cavallo F, Aime S, Crich SG. L-Ferritin targets breast cancer stem cells and delivers therapeutic and imaging agents. Oncotarget 2016 Jul 29. doi:10.18632/oncotarget.10920. [Epub ahead of print]

Lanzardo S, Conti L, Rooke R, Ruiu R, Accart N, Bolli E, Arigoni M, Macagno M, Barrera G, Pizzimenti S, Aurisicchio L, Calogero RA, Cavallo F., Immunotargeting of antigen xCT attenuates stem-like cell behavior and metastatic progression in breast cancer. Cancer Res 2016. 76(1):62-72.

Geninatti Crich S, Cadenazzi M, Lanzardo S, Conti L, Ruiu R, Alberti D, Cavallo F, Cutrin JC, Aime S., Targeting ferritin receptors for the selective delivery of imaging and therapeutic agents to breast cancer cells. Nanoscale 2015. 7(15):6527-33

Conti L., Ruiu R., Barutello G., Macagno M., Bandini S., Cavallo F., and Lanzardo S. (2014) Microenvironment, Oncoantigens, and Antitumor Vaccination: Lessons Learned from BALB-neuT Mice. Biomed Res Int 2014

1) xCT is a new cancer stem cell immunotherapeutic target for breast cancer.  Lanzardo S, Conti L, Rooke R, Ruiu R, Accart N, Bolli E, Arigoni M, Macagno M, Barrera G, Pizzimenti S, Calogero RA and Cavallo F. Progress In Vaccination Against Cancer (PIVAC) 15, Tubingen, Germany, 6-8/10/2015, Oral presentation by Ruiu R.

2) Targeting the xCT cystine/glutamate antiporter through a Bovine Herpesvirus 4-based vaccination to eradicate breast cancer stem cells in the preclinical setting. Conti L, Lanzardo S, Ballatore A, Ruiu R, Donofrio G, Cavallo F., International Retreat of PhD Students in Immunology SIICA, Verona 6-7/10/2017, Oral presentation by Ruiu R

1) Mouse-human microarray data integration reveals xCT as a new oncoantigen of breast cancer stem cells.  Lanzardo S, Conti L, Ruiu R,  Antonazzo R, Calogero RA, and Cavallo F. IX National Conference SIICA, Florence 28-31/05/2014, Poster presentation by Ruiu R.

2)The type II transmebrane serine protease TMPRSS4 is a promising cancer stem cell-associated target. Ruiu R, Conti L, Arigoni M, Calogero RA, Cavallo F, and Lanzardo S. "Dangerous Liaisons: translating cancer biology into better patients management - 56° Congresso Nazionale Società Italiana di Cancerologia", Ferrara 11-13/09/2014, Poster presentation by Ruiu R.

3)TMPRSS4 is a breast cancer stem cell-associated target suitable for anti-tumor immune targeting. Ruiu R, Lanzardo S, Conti L, Bandini S, Arigoni M, Calogero RA, and Cavallo F. 14^th International Congress on Progress in Vaccination Against Cancer, Rome 24-26/09/2014, Poster presentation by Ruiu R.

4) TMPRSS4 is a breast cancer stem cell-associated antigen and a putative target for DNA-based vaccination. Ruiu R, Lanzardo S, Conti L, Calogero RA, Cavallo F. 13th CIMT ANNUAL MEETING", Mainz, Germany, 11-13/05/2015, Poster presentation by Ruiu R.

5) Mouse breast tumor growth and metastasis inhibition via immunotargeting of the cancer stem cell antigen xCT. Lanzardo S, Conti L, Rooke R, Ruiu R, Accart N, Bolli E, Arigoni M, Macagno M, Barrera G, Pizzimenti S, Aurisicchio L, Calogero RA, Cavallo F., "Cancer Vaccine Conference Amsterdam", Amsterdam, Netherlands , 24-25/11/2015, Poster presentation by Ruiu R.

6) Comparative Transcriptomics of Triple Negative Breast Cancer Stem Cells and Differentiated Tumor Cells Identifies TENM4 as a Potential Therapeutic Target. Ruiu R, ArigoniM, Riccardo F, Conti L, Lanzardo S, Calogero RA, Cavallo F, Quaglino E., EACR-AACR-SIC Special Conference 2017: The Challenges of Optimizing Immuno- and Targeted Therapies: From Cancer Biology to the Clinic, Florence 24-27/06/2017, Poster presentation by Ruiu R.

7) Comparative Transcriptomics of Triple Negative Breast Cancer Stem Cells and Differentiated Tumor Cells Identifies TENM4 as a Potential Therapeutic Target. Ruiu R, ArigoniM, Riccardo F, Conti L, Lanzardo S, Calogero RA, Cavallo F, Quaglino E., D-Day of Doctoral School in Life and Health Sciences, Torino 19/09/2017, Poster presentation by Ruiu R.

8) Comparative Transcriptomics of Triple Negative Breast Cancer Stem Cells and Differentiated Tumor Cells Identifies TENM4 as a Potential Therapeutic Target. Ruiu R, ArigoniM, Riccardo F, Conti L, Lanzardo S, Calogero RA, Cavallo F, Quaglino E., ENABLE Conference - The 1st European PhD and Postdoc Symposium, Barcelona (Spain) 15-17/11/2017, Poster presentation by Ruiu R.

Class A Scavenger Receptor Member 5 is a promising target in mammary cancer stem cell-specific MRI imaging and therapy. Ruiu R, Cadenazzi M, Geninatti Crich S, Conti L, Lanzardo S, Cutrin JC, Cavallo F, and Aime S. Workshop SIC: "Targeted Therapy of Cancer: Where we are heading", Turin 27/06/2014, selected for abstract book.

Cancer Stem Cell Oncoantigens Identification: two examples from breast cancer. Lanzardo S, Conti L, Ruiu R, Antonazzo R, Calogero RA and Cavallo Federica. Workshop SIC: "Targeted Therapy of Cancer: Where we are heading", Turin 27/06/2014. Oral presentation by Lanzardo S.

Mouse-human microarray data integration reveals xCT as a new oncoantigen of breast cancer stem cells.  Lanzardo S, Conti L, Ruiu R,  Antonazzo R, Calogero RA, and Cavallo F. 14^th International Congress on Progress in Vaccination Against Cancer, Rome 24-26/09/2014, Poster presentation by Lanzardo S.

Class A Scavenger Receptor Member 5 is a promising target for mammary cancer stem cell eradication. Conti L, Lanzardo S, Ruiu R, Geninatti Crich S, Cadenazzi M, Cutrin JC, Aime S, Calogero RA, Cavallo F. 14^th International Congress on Progress in Vaccination Against Cancer, Rome 24-26/09/2014, Poster presentation by Conti L.

L- Ferritin targets breast cancer stem cells and delivers therapeutic and imaging agents. Crich SG, Conti L, Lanzardo S, Cutrin JC, Ruiu R, and Aime S. EMIM (European Molecular Imaging Meeting) 2016, Utrecht (NETHERLANDS) 8-10/03/2016. Poster presentation by Crich SG.